A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer
Title:
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer
Author:
Gradishar, William J. Kaklamani, Virginia Sahoo, Tarini P. Lokanatha, Dasappa Raina, Vinod Bondarde, Shailesh Jain, Minish Ro, Sunhee Kwon Lokker, Nathalie A. Schwartzberg, Lee